首页 > 市场调查报告书 > 製药

癌症

市场调查报告书

商品编码

1410096

肿瘤学人工智慧市场：2023 年至 2028 年预测

AI in Oncology Market - Forecasts from 2023 to 2028

出版日期: 2023年12月11日 | 出版商:

Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录

预计在预测期内，肿瘤学市场的人工智慧将以 35.17% 的复合年增长率成长。

在人工智慧 (AI) 的帮助下，肿瘤学领域正在取得巨大突破。人工智慧提供的多重好处正在推动人工智慧在癌症研究中的日益采用，并推动人工智慧在肿瘤学市场的发展。此外，癌症患者盛行率的增加、癌症风险的增加以及人口老化也有望推动肿瘤学领域的人工智慧市场。此外，市场参与者针对人工智慧整合和产品推出的研究计划和资金正在进一步推动肿瘤市场的人工智慧。

人工智慧在肿瘤学中的好处

将人工智慧纳入癌症研究的各种好处是肿瘤学市场人工智慧的关键成长要素。例如，乳房 X 光检查、电脑断层扫描和 MRI 影像可以透过人工智慧演算法进行分析，以寻找癌症的早期征兆。这些演算法经常发现人类放射科医生可能错过的模式和异常，从而实现更早的诊断和更好的结果。人工智慧可以透过分析患者资讯、医疗记录和临床指南并制定治疗方法来协助肿瘤学家。 AI演算法可以综合考虑肿瘤大小、位置、患者特征等多种因素，提案最佳治疗策略。此外，人工智慧模型可以分析临床记录和治疗史等患者资料，以预测疾病发作、治疗反应和整体预后。

癌症患者增加

癌症患者数量的增加、治疗和早期检测的紧迫性预计将推动肿瘤市场的人工智慧发展。例如，根据世界卫生组织的数据，2020 年约有 1,000 万人（约六分之一的死亡人数）死于癌症，使其成为全球主要死亡原因。据世界癌症研究基金会称，2020年将有超过1800万新癌症患者被诊断出来，其中男性930万，女性880万。此外，根据世界卫生组织的说法，如果及早发现并给予适当的治疗，许多癌症是可以治癒的。病例的增加表明人工智慧在肿瘤学领域的应用增加，因为人工智慧可以帮助早期发现并改善治疗结果。

加大研究及资金筹措力度

由于支持肿瘤学人工智慧市场的资助研究，人工智慧的使用已经有了一些前景。例如，NCI 的校内研究计画正在利用人工智慧功能来增强前列腺癌和子宫颈癌的癌症筛检。 Cancer Moonshot 与能源部 (DOE) 合作，资助两项重要倡议，当该计划于 2022 年恢復时，这些计划将利用超级计算技能和能力进行癌症研究。此外，作为癌症登月计画的一部分，NCI 在五年内（2022-2027 年）向四个学术研究机构拨款 2,300 万美元。每个中心将重点放在广泛的与癌症相关的远端医疗研究问题，这些问题将作为其研究的框架。

人口老化

年龄越大，与癌症共存就越困难。老年人的许多癌症被发现较晚，因为癌症的早期症状可能与全身疼痛或其他与老龄化相关的疾病混淆。根据世界卫生组织预测，2020年，60岁及以上人口将超过5岁以下人口，2015年至2050年间，全球60岁及以上人口比例将从12%增至22%。据美国癌症协会称，2019 年约有 140,690 名癌症患者被诊断出，103,250 名美国老年人死于该疾病。不断增长的老龄化人口预计将推动肿瘤学领域的人工智慧市场发展，因为人工智慧可以分析影像并有助于早期发现癌症。

市场抑制因素

预计很少有因素会限制肿瘤市场的人工智慧。例如，将人工智慧应用于癌症需要在基础设施、运算能力和技术知识方面进行大量投资。这些成本可能会阻碍普及，特别是在资源有限的医疗机构。此外，人工智慧模型通常充当“黑盒子”，使其决策流程难以理解和分析。需要了解人工智慧生成建议背后推理的医疗保健专业人员和患者可能会担心这种缺乏可解释性。

北美地区预计将大幅成长

预计在预测期内，北美地区将占据肿瘤学人工智慧市场的重要份额。造成这一份额的因素包括癌症患者的增加、人口老化、医疗保健的改善以及人工智慧的引入。例如，根据 CDC 的数据，癌症是美国第二大死因，2021 年约有 190 万例癌症。根据美国癌症协会的数据，美国成长最快的年龄层是 85 岁及以上的成年人。此外，Azra AI、IBM 和英特尔公司等主要市场参与者的存在预计将透过技术进步进一步推动肿瘤学市场的人工智慧。

主要市场参与者

西门子 Healthineers 是一家国际医疗技术提供商，专注于医疗保健行业的产品、服务和解决方案。我们提供广泛的影像系统，包括 CT、MRI、分子影像、X 光、超音波和血管造影术。 Digital Diagnostics Inc. 是一家领先的人工智慧诊断公司，其使命是透过科技应用改善医疗保健。该公司开发的 Dermspot 是一种人工智慧驱动的演算法，可以检测黑色素瘤、鳞状细胞癌和基底细胞癌等皮肤癌。

新兴市场的主要发展

2023 年 6 月，Tempus 推出了 Tempus One，这是一款语音和文字助手，可帮助肿瘤内科医生轻鬆存取患者资料。 2023 年 5 月，Belong.Life 宣布推出对话式 AI 肿瘤学导师「Dave」。它是同类产品中的第一个，旨在吸引和教育癌症患者的临床旅程。截至 2023 年 5 月，Dave 对 10,000 名癌症患者进行了测试。 2023年1月，Massive Bio宣布将于2023年上半年推出一款新的人工智慧药物配对工具。 2022 年 12 月，Digistain 宣布推出突破性的 AI 乳癌诊断工具，以协助降低成本。该工具旨在以超过 99% 的准确率进行诊断，并减少等待时间和化疗的使用。

介绍
北美洲
- 美国
- 加拿大
- 墨西哥
南美洲
- 巴西
- 阿根廷
- 其他的
欧洲
- 英国
- 德国
- 法国
- 西班牙
- 其他的
中东/非洲
- 沙乌地阿拉伯
- 阿拉伯聯合大公国
- 以色列
- 其他的
亚太地区
- 日本
- 中国
- 印度
- 韩国
- 印尼
- 泰国
- 其他的

第九章竞争环境及分析

主要企业及策略分析
新兴企业和市场盈利
合併、收购、协议和合作
供应商竞争力矩阵

第十章公司简介

Azra AI
IBM
Siemens Healthcare GmbH
Intel Corporation
GE HealthCare
NVIDIA Corporation
Digital Diagnostics Inc.
ConcertAI
Median Technologies
PathAI

简介目录

Product Code: KSI061615764

The AI in oncology market is estimated to grow at a CAGR of 35.17% during the forecast period.

The discipline of oncology has seen tremendous breakthroughs through the help of artificial intelligence (AI). Multiple advantages offered by the AI are driving the increased adoption of it in cancer studies thereby propelling the AI in oncology market. Moreover, the growing prevalence of cancer cases coupled with an aging population and their higher risk of cancer is also expected to boost the AI in oncology market. Additionally, the research initiatives and funds for AI incorporation and product launches by market players are further aiding the AI in oncology market.

Advantages of AI in Oncology

The various advantages of incorporating AI in cancer studies are a major growth driver of AI in oncology market. For example, mammograms, CT scans, and MRI images can be analyzed by AI algorithms to look for early indications of cancer. These algorithms frequently find patterns and anomalies that human radiologists might overlook, enabling earlier diagnosis and better results. AI can help oncologists by analyzing patient information, medical records, and clinical guidelines to help them create treatment regimens. AI algorithms can suggest the best course of treatment by taking into account many elements like the tumor's size, location, and patient characteristics. Moreover, to forecast illness development, treatment response, and overall prognosis, AI models can analyze patient data, including clinical records and treatment history.

Growing Prevalence of Cancer Cases

The rising cases of cancer and the urgency of treatment and early detection are expected to boost the AI in oncology market. For instance, roughly 10 million deaths, or roughly one in six deaths, were caused by cancer in 2020, making it the top cause of death globally according to the WHO. According to World Cancer Research Fund International, there were more than 18 million new cancer cases in 2020 with 9.3 million in men and 8.8 million in women. Moreover, WHO says that many cancers are curable if caught early and treated appropriately. As AI can help in early detection and improved outcomes, therefore, rising cases indicate more adoption of AI in oncology.

Increased Research and Funding Initiatives

There are already several prospects for the usage of AI as a result of funded research that is aiding the AI in oncology market. For example, the capabilities of AI are being used by the NCI's intramural research program to enhance cancer screening for prostate and cervical cancer. In collaboration with the Department of Energy (DOE), the Cancer Moonshot is financing two significant initiatives that make use of supercomputing skills and capacity for cancer research with the relaunch of the program in 2022. Moreover, in the course of five years (2022-2027), the NCI gave four university research organizations $23 million as part of the Cancer Moonshot program. Each center will concentrate on a broad telehealth research subject related to cancer that will serve as the framework for their investigations.

Aging Population

Living with cancer becomes more challenging as people get older. As early cancer symptoms can be confused with common pain or other ailments related to ageing, many cancers in older persons are discovered at a later stage. According to the WHO, in 2020, there were more persons over the age of 60 than under five-year-olds and the percentage of people over 60 in the world will increase from 12% to 22% between 2015 and 2050. Around 140,690 cancer cases were diagnosed in 2019, while 103,250 elderly Americans lost their lives to the disease as per the American Cancer Society. As AI can analyze images and help in the early detection of cancer, therefore, rising aging population is contemplated to boost the AI in oncology market.

Restraints in the Market

Few factors are expected to limit the AI in oncology market. For example, a large investment in infrastructure, computer capacity, and technological know-how is necessary to implement AI in cancer. Widespread adoption may be hampered by these expenses, particularly in healthcare settings with limited resources. Moreover, It can be difficult to comprehend and analyze the decision-making processes of AI models since they frequently function as "black boxes." Healthcare professionals and patients who need to comprehend the reasoning behind AI-generated recommendations may become concerned about this lack of interpretability.

North America is Expected to Grow Significantly

The North American region is expected to hold a significant share of AI in oncology market during the forecasted period. Various factors attributed to such a share are rising cancer cases, an aging population, a strong healthcare presence, and the adoption of AI. For example, cancer is the second-most leading cause of death in the US as per the CDC with around 1.9 million cases in 2021. The fastest-growing age group in the US is adults over the age of 85 as per the American Cancer Society. Moreover, the presence of major market players such as Azra AI, IBM, and Intel Corporation are further expected to propel the AI in oncology market through technological advancements.

Major Market Players

An international provider of medical technology, Siemens Healthineers focuses on products, services, and solutions for the healthcare industry. A wide range of imaging systems is available from Siemens Healthineers, including systems for computed tomography (CT), magnetic resonance imaging (MRI), molecular imaging, X-ray, ultrasound, and angiography.
Digital Diagnostics Inc. is one of the advanced AI diagnostics companies with a mission of improving healthcare through the application of technology. Dermspot developed by the company is an AI-powered algorithm that detects melanoma, squamous cell carcinoma, and basal cell carcinoma of skin cancer.

Key Market Developments

In June 2023, for oncologists to have simpler access to patient data, Tempus introduced Tempus One, a voice-and-text assistant.
In May 2023, Belong.Life launched a conversational AI oncology mentor dubbed Dave. It is the first of its kind, developed to engage and educate cancer patients on their clinical journey. Dave was tested on 10,000 people with cancer up to May 2023.
In January 2023, Massive Bio announced the introduction of a new AI-powered medication matching tool in the first half of 2023 that will let doctors proactively find additional cancer therapy alternatives for their patients.
In December 2022, Digistain launched a new revolutionary AI breast cancer diagnostic tool that will help in cost saving. It is designed to reduce waiting times and the use of chemotherapy with more than 99% accuracy in diagnostics.

Segmentation:

By Component Type

Software Solutions
Hardware
Services

By Cancer Type

Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Brain Tumor
Others

By Treatment Type

Chemotherapy
Radiotherapy
Immunotherapy
Others

By Geography

North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
Japan
China
India
South Korea
Indonesia
Thailand
Others

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Data
2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Force Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. AI IN ONCOLOGY MARKET, BY COMPONENT TYPE

5.1. Introduction
5.2. Software Solutions
5.3. Hardware
5.4. Services

6. AI IN ONCOLOGY MARKET, BY CANCER TYPE

6.1. Introduction
6.2. Breast Cancer
6.3. Lung Cancer
6.4. Prostate Cancer
6.5. Colorectal Cancer
6.6. Brain Tumor
6.7. Others

7. AI IN ONCOLOGY MARKET, BY TREATMENT TYPE

7.1. Introduction
7.2. Chemotherapy
7.3. Radiotherapy
7.4. Immunotherapy
7.5. Others

8. AI IN ONCOLOGY MARKET, BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. United States
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
8.4. Europe
- 8.4.1. United Kingdom
- 8.4.2. Germany
- 8.4.3. France
- 8.4.4. Spain
- 8.4.5. Others
8.5. The Middle East and Africa
- 8.5.1. Saudi Arabia
- 8.5.2. UAE
- 8.5.3. Israel
- 8.5.4. Others
8.6. Asia Pacific
- 8.6.1. Japan
- 8.6.2. China
- 8.6.3. India
- 8.6.4. South Korea
- 8.6.5. Indonesia
- 8.6.6. Thailand
- 8.6.7. Others